Morgan Stanley’s Acrivon Therapeutics ACRV Stock Holding History

Morgan Stanley’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51K	Sell	36,671 -10,160	-22%	-$17.7K	﹤0.01%	6412
2025 Q4	$113K	Sell	46,831 -10,329	-18%	-$22.5K	﹤0.01%	6138
2025 Q3	$103K	Sell	57,160 -5,856	-9%	-$8.23K	﹤0.01%	6135
2025 Q2	$75K	Buy	63,016 +27,795	+79%	+$38.1K	﹤0.01%	6224
2025 Q1	$71.5K	Buy	35,221 +490	+1%	+$2.64K	﹤0.01%	6153
2024 Q4	$209K	Sell	34,731 -1,183	-3%	-$8.6K	﹤0.01%	5768
2024 Q3	$251K	Buy	35,914 +18,665	+108%	+$147K	﹤0.01%	5666
2024 Q2	$100K	Buy	17,249 +6	+0%	+$48	﹤0.01%	5966
2024 Q1	$123K	Sell	17,243 -34,019	-66%	-$158K	﹤0.01%	5910
2023 Q4	$252K	Buy	51,262 +46,319	+937%	+$245K	﹤0.01%	5860
2023 Q3	$47.3K	Sell	4,943 -3,562	-42%	-$41.2K	﹤0.01%	6190
2023 Q2	$110K	Buy	8,505 +2,881	+51%	+$34.9K	﹤0.01%	5904
2023 Q1	$71.4K	Buy	5,624 +4,755	+547%	+$79.8K	﹤0.01%	6138
2022 Q4	$10K	Buy	+869	New	+$11K	﹤0.01%	6934

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's ACRV Position: Q1 2026 in Review

Morgan Stanley reduced its Acrivon Therapeutics (ACRV) stake by 22% in Q1 2026, selling an estimated $17.7K and leaving 36,671 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #6412.

Morgan Stanley first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $252K in Q4 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Morgan Stanley held 36,671 shares of Acrivon Therapeutics worth $51K as of Q1 2026.
Morgan Stanley sold 10,160 Acrivon Therapeutics shares in Q1 2026, an estimated $17.7K.
Acrivon Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6412 holding.
Morgan Stanley first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
Morgan Stanley's Acrivon Therapeutics position peaked at $252K in Q4 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.